
Does Medicare Cover Methoxsalen?
Plus, Medicare may cover the injection form of methoxsalen (Uvadex) when prescribed for treating cutaneous T-cell lymphoma (CTCL) that hasn't responded to other treatments as part of a special kind of light therapy called photopheresis.
Medicare coverage for methoxsalen capsule
Medicare Part D and Medicare Advantage Prescription Drug (MAPD) plans may cover methoxsalen as part of light therapy for psoriasis if other treatments haven't worked for the condition and your doctor has clearly documented this for Medicare.
That said, whether your plan covers the brand name or the generic drug depends on your specific plan.
In addition, while methoxsalen with light therapy may be effective for treating other skin issues like vitiligo, Medicare usually covers medications based on the conditions approved by the Food and Drug Administration (FDA).
Medicare coverage for methoxsalen injection
Medicare may also cover the injection form of this medication when combined with photopheresis to help treat CTCL if other treatments haven't worked and a doctor has also documented this for Medicare.
But in this case, doctors don't inject the drug directly into your body. Instead, they inject it into the instrument during the photopheresis process. Because of this, if your treatment is covered, the injection drug will likely fall under the coverage of Medicare Part B.
The procedure itself is usually covered by Part B as long as it's done in a clinic and doesn't require a hospital stay. If you need to receive it while you're in the hospital, though, it might then be covered under Part A.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
ITV News meets Amal, a severely malnourished girl in Gaza
Amal, a 7-year-old girl, is wasting away after months with only the bare minimum of food. Her parents took her to the Nasser hospital in Gaza hoping doctors could help, but an aid blockade has left them with few supplies. There is water to hydrate her, but no food formula or medicines to give her back some strength. Dr Ahmad Al-Farra, the head of paediatrics at Nasser Hospital, says Amal is "one of the most serious cases in our nutrition department", having lost nearly 50% of her weight. At this hospital alone more than sixty children have died due to starvation. ITV News reports from the hospital in southern Gaza, where her father admits he is "deeply afraid of losing her", as her condition deteriorates.
Yahoo
24 minutes ago
- Yahoo
Regular cannabis use can cause a serious vomiting syndrome. Should people be warned?
When Brittany Ramsey started experiencing "awful stomach episodes" she thought it must've been side effects of the medication she was taking to manage her diabetes. But after a particularly gruelling episode where she just could not stop vomiting — not being keep down even small sips of water — that landed her in hospital, Ramsey knew something felt different about what she was experiencing. "From then, the episodes got worse and worse, and closer together," said Ramsey, a 35-year-old operations trainer at a financial firm in Cincinnati, Ohio. "From 2021 to 2024 … three years, I was hospitalized 29 times. Five ambulance trips – one actually had to pick me up on the side of the road because I couldn't make it to the hospital." After years of undergoing, at times, invasive testing procedures to rule out Crohn's disease, gastroparesis and diverticulitis, a doctor told Ramsey about cannabis hyperemesis syndrome (CHS). In recent years some emergency rooms have been seeing an uptick in visits due to cyclic episodes of uncontrollable vomiting in cannabis users, often characterized by experiencing temporary relief with hot showers and baths. Since it was first identified in medical literature in 2004, CHS cases have increased, possibly because of greater cannabis access or higher THC potency of products. Public health researchers suggest more awareness of CHS within the health-care system is needed for cannabis users to get the information and support they need. More CHS cases in the ER CHS is characterized by "severe and persistent vomiting" and is usually seen in people who have been using cannabis several times a week for multiple years, said Jamie Seabrook, a professor at the Department of Epidemiology and Biostatistics at Western University in London, Ont. Ramsey said she'd been smoking at least once a day for over 10 years since she was 18 when she first started experiencing CHS symptoms in 2017. A 2022 study by researchers at the Ottawa Hospital Research Institute looked at the rate of emergency department visits for CHS after recreational cannabis was legalized and commercialized in Ontario, looking at nearly 13,000 CHS-related hospitalizations in Ontario from 8,140 individuals between 2014 and 2021. The study, published in the Journal of the American Medical association (JAMA), found that emergency department visits related to CHS had increased by 13-fold over a period of nearly eight years. The study doesn't show what caused the change, but the authors noted that the biggest increase in visits came not after legalization in 2018 but after Ontario allowed expansion of retail stores in 2020, which coincided with the COVID-19 pandemic. Though we don't have numbers how many people have been diagnosed or hospitalized with CHS, online communities are filled with people looking for support. Ramsey is part of one of them — a CHS Facebook group described as a "safe place to recover and learn" with 3,000 members. The largest CHS Facebook group has 31,000 members. On Reddit, the group r/CHSinfo has 20,000 members, with discussions ranging from tips on how to manage episodes and personal anecdotes about repeated hospitalizations. Seabrook, who co-authored a recent review of existing research on CHS in youth, said there's been an "explosion" of people showing up in some North American emergency rooms with CHS within the last seven to eight years. The Ottawa Hospital Research Institute study showed that other cannabis-related emergency room visits, including for intoxication and dependence, saw a substantial increase starting in early 2020 as well. Surge in THC potency since the 1980s Seabrook said a likely reason for increased rates of CHS is the high THC potency of cannabis products today. THC is the compound in cannabis that is responsible for the sensation of a high most people experience when consuming it. When its potency increases, so do its harmful effects. Different strains of the plant will have different concentrations of active compounds, measured by percentage of total weight or volume. On average, THC content is much higher today than it used to be. "The potency of THC was only about three per cent in the 1980s and today, according to Health Canada, the average is 15 per cent with some strains as high as 30 per cent," Seabrook said, citing Health Canada numbers for "fresh or dried herb material." "So we're talking a 400 per cent or higher increase in the potency." For "chemically concentrated extracts," such as hash oil, shatter, budder and wax, the typical potency can be up to 90 per cent, according to Health Canada data. "The potency, I think, is what's causing the illnesses to become more and more prevalent, because they're smoking a lot more potent stuff," Ramsey said. "And that's the same with me. When I first started smoking, it was my brother's homegrown stuff, versus getting it from friends and dispensaries out in California, where it does get stronger and stronger." "I feel like maybe before just making marijuana available to the masses, maybe some of these things should have been looked into. You know, too much of anything might be bad," said Ramsey. Lawsuit against Aurora Cannabis cites CHS A lawsuit was recently brought against Canadian cannabis production company Aurora Cannabis for alleged negligence of failing to warn consumers about the potential risk for developing CHS from the regular use of its products. The lawsuit was certified by the Ontario Superior Court of Justice last month, meaning it can proceed as a class action. Margaret Waddell, the lawyer prosecuting the case, said she hopes that if the lawsuit is successful, it could have an industry-wide effect on including CHS in their product labelling. "Ideally, Health Canada will require them at some point," Waddell said. Health Canada does require cannabis manufacturers to warn customers about specified risks — including psychotic symptoms, addiction and dependence — but Waddell said there aren't currently any requirements to specifically include CHS in those warnings. Aurora Cannabis declined to comment on the lawsuit, writing in an emailed statement: "It is the company's practice not to comment on legal matters beyond information that is made available to the public." "Information that [CHS] exists is very important," Seabrook said. "In schools, in health-care settings – whether that's neurologists, psychiatrists, [emergency room] doctors – and public health campaigns, so people can make a better informed decision about their cannabis use."


Medscape
29 minutes ago
- Medscape
Cervical Cancer Risk Overlooked After Age 65
TOPLINE: Analysis of over 2.1 million women in China revealed that those aged 65 years or older vs those younger than 65 years had significantly higher rates of high-risk human papillomavirus (hr-HPV) infection (13.67% vs 8.08%) and cervical cancer (0.092% vs 0.01%) although most guidelines recommend discontinuing screening for women aged 65 years or older with a normal screening history. METHODOLOGY: Researchers conducted a retrospective analysis of cervical cancer screening data from Shenzhen, China (2017-2023), to assess hr-HPV distribution and cervical intraepithelial neoplasia grade 2 or worse (CIN2+) prevalence in women aged 65 years or older vs those younger than 65 years. Data collection encompassed 628 healthcare facilities, including 496 community health centers, 94 hospitals, 11 maternal and child health hospitals, and 27 other medical facilities. Clinical records included demographic information, cytology results, HPV testing covering 14 hr-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), and colposcopy/biopsy outcomes. Analysis included 2,152,766 complete records from an initial collection of 2,580,829, yielding an 83.4% data validity rate. TAKEAWAY: Analysis of 2,152,766 records revealed that women aged 65 years or older (n = 17,420; 0.81%) vs those younger than 65 years showed higher hr-HPV prevalence (13.67% vs 8.08%), CIN2+ detection rate (0.333% vs 0.155%), and cancer rate (0.092% vs 0.01%; P for all < .001). Single, double, and triple hr-HPV infections were found in 10.56%, 2.32%, and 0.57% of women aged 65 years or older, with CIN2+ detection rates of 2.01%, 2.73%, and 4.04%, respectively, all exceeding rates in those younger than 65 years (P < .001). A significant dose-response relationship emerged between hr-HPV infections and CIN2+ risk in women aged 65 years or older (P for trend < .001), with odds ratios being 55.86 (95% CI, 21.81-143.07), 65.95 (95% CI, 22.63-192.18), and 85.45 (95% CI, 24.15-302.35) for single, double, and triple infections, respectively. IN PRACTICE: 'Currently, there is a significant global gap in cervical cancer prevention for older women, and urgent action is needed. First, screening and early diagnosis for women aged ≥ 65 should be strengthened, including affordable screening services and age-appropriate technologies to detect and treat precancerous lesions. Additionally, community engagement, health education, and media campaigns can raise awareness of cervical cancer risks and prevention among older women, encouraging active participation in screening programs,' authors of the study wrote. SOURCE: The study was led by Zichen Ye, He Wang, and Yingyu Zhong, who served as joint first authors. It was published online in Gynecology and Obstetrics Clinical Medicine. LIMITATIONS: The study faced several limitations despite using high-quality, large-sample, real-world cervical cancer screening data collected over 7 years in Shenzhen. Because women aged 65 years or older were not included in the national target screening population, participants may have had symptoms or concerns, introducing potential selection bias. The low number of hr-HPV infections in this age group led to some results trending toward extremes, affecting result stability. Additionally, data from a single region in China limited generalizability to other populations. The researchers could not obtain specific information about the types of cytologic detection products and HPV genotyping products used, which may have affected result precision and comparability. DISCLOSURES: The study was supported by the Sanming Project of Medicine in Shenzhen (SZSM202211032). The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.